Open AccessRa-SBRT is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients
Author(s) -
C. O. Arun
Publication year - 2019
Publication title -
journal of analytical oncology
Language(s) - English
Resource type - Journals
eISSN - 1927-7210
pISSN - 1927-7229
DOI - 10.30683/1927-7229.2019.08.10
Subject(s) - medicine , stage (stratigraphy) , adjuvant , context (archaeology) , oncology , immune system , lung cancer , bystander effect , radiation therapy , immunotherapy , lung , cancer , immunology , paleontology , biology
Bystander toxicity and tissue fibrosis are the major complications with conventional radiation therapy for cancer patients. In this context, we here propose RapidArc - Stereotactic Body Radiation Therapy (Ra-SBRT) as a non-invasive and immune adjuvant approach for the successful eradication of advance stage NSCLC. Ra-SBRT is highly focused and capable of destroying tumors with high grade metastatic lesions and spared normal tissues. Follow up of stage 4th NSCLC patient revealed that Ra-SBRT is potentially immunogenic which was evident by increased number of iNOS+ Tumor Associated macrophages (M1-TAM), Siglac-8+ eosinophils, basophils and subsequent prolongation of disease free survival of 4th stage NSCLC patients by 3 years. This study demonstrated M1 retuning potential of Ra-SBRT which is a pre-requisite of effective management of inoperable and highly metastatic tumors of lung with least or no bystander impact.